Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues.
Jaimeson VeldhuizenHelen F MannNina KaramanovaWade D Van HornRaymond Q MigrinoDavid BrafmanMehdi NikkhahPublished in: Science advances (2022)
Long QT syndrome (LQTS) is a cardiovascular disease characterized by QT interval prolongation that can lead to sudden cardiac death. Many mutations with heterogeneous mechanisms have been identified in KCNH2 , the gene that encodes for hERG (Kv11.1), which lead to onset of LQTS type 2 (LQTS2). In this work, we developed a LQTS2-diseased tissue-on-a-chip model, using 3D coculture of isogenic stem cell-derived cardiomyocytes (CMs) and cardiac fibroblasts (CFs) within an organotypic microfluidic chip technology. Primarily, we created a hiPSC line with R531W mutation in KCNH2 using CRISPR-Cas9 gene-editing technique and characterized the resultant differentiated CMs and CFs. A deficiency in hERG trafficking was identified in KCNH2 -edited hiPSC-CMs, revealing a possible mechanism of R531W mutation in LQTS2 pathophysiology. Following creation of a 3D LQTS2 tissue-on-a-chip, the tissues were extensively characterized, through analysis of calcium handling and response to β-agonist. Furthermore, attempted phenotypic rescue via pharmacological intervention of LQTS2 on a chip was investigated.
Keyphrases
- crispr cas
- circulating tumor cells
- high throughput
- genome editing
- cardiovascular disease
- drug induced
- gene expression
- randomized controlled trial
- left ventricular
- genome wide
- copy number
- type diabetes
- multidrug resistant
- magnetic resonance imaging
- single cell
- dna methylation
- genome wide identification
- high resolution
- coronary artery disease
- transcription factor
- optical coherence tomography